ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near New York, NY, USA:

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

New York, New York, United States and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Mineola, New York, United States and 125 other locations

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Drug: carboplatin
Drug: carboplatin

Phase 2

AstraZeneca
AstraZeneca

New York, New York, United States and 41 other locations

be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...

Active, not recruiting
Recurrent Epithelial Ovarian Cancer
Recurrent Peritoneal Cancer
Drug: Epacadostat (INCB024360)
Drug: Cyclophosphamide

Phase 1, Phase 2

Immunovaccine

New York, New York, United States and 8 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

New York, New York, United States and 46 other locations

clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: Niraparib
Drug: ZN-c3

Phase 1, Phase 2

K-Group Beta

New York, New York, United States and 18 other locations

efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: Pembrolizumab
Drug: ONC-392

Phase 2

OncoC4

Ridgewood, New Jersey, United States and 20 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

New York, New York, United States and 70 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: Olaparib

Phase 3

Novartis
Novartis

New York, New York, United States and 93 other locations

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-...

Enrolling
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Biological: AB-1015

Phase 1

ArsenalBio

New York, New York, United States and 9 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems